Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-31true2023-04-01true00falsefalse 08078767 2023-04-01 2024-03-31 08078767 2022-04-01 2023-03-31 08078767 2024-03-31 08078767 2023-03-31 08078767 2022-04-01 08078767 c:Director1 2023-04-01 2024-03-31 08078767 c:Director2 2023-04-01 2024-03-31 08078767 c:Director3 2023-04-01 2024-03-31 08078767 c:RegisteredOffice 2023-04-01 2024-03-31 08078767 d:ShareCapital 2023-04-01 2024-03-31 08078767 d:ShareCapital 2024-03-31 08078767 d:ShareCapital 2022-04-01 2023-03-31 08078767 d:ShareCapital 2023-03-31 08078767 d:ShareCapital 2022-04-01 08078767 c:OrdinaryShareClass1 2023-04-01 2024-03-31 08078767 c:OrdinaryShareClass1 2024-03-31 08078767 c:OrdinaryShareClass1 2023-03-31 08078767 c:EntityNoLongerTradingButTradedInPast 2023-04-01 2024-03-31 08078767 c:FRS102 2023-04-01 2024-03-31 08078767 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 08078767 c:FullAccounts 2023-04-01 2024-03-31 08078767 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 08078767 e:PoundSterling 2023-04-01 2024-03-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 08078767









PROCARE PHARMA LIMITED







UNAUDITED

DIRECTORS' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

 
PROCARE PHARMA LIMITED
 
 
COMPANY INFORMATION


Directors
Miss H Patel 
Mr J C Patel 
Mr J C Patel Jnr 




Registered number
08078767



Registered office
2 Peterwood Way

Croydon

Surrey

CR0 4UQ





 
PROCARE PHARMA LIMITED
 

CONTENTS



Page
Directors' report
1
Profit and loss account
2
Balance sheet
3
Statement of changes in equity
4
Notes to the financial statements
5 - 6


 
PROCARE PHARMA LIMITED
 
 
 
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2024

The Directors present their report and the financial statements for the year ended 31 March 2024.

Principal activity

The principal activity of the Company continued to be that of a dormant company.

Directors

The Directors who served during the year were:

Miss H Patel 
Mr J C Patel 
Mr J C Patel Jnr 

Small companies note

In preparing this report, the Directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board and signed on its behalf.
 





Miss H Patel
Director

Date: 6 August 2024

Page 1

 
PROCARE PHARMA LIMITED
 
 
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2024

The Company has not traded during the year or the preceding financial year. During these periods, the Company received no income and incurred no expenditure and therefore made neither profit or loss.

The notes on pages 5 to 6 form part of these financial statements.

Page 2

 
PROCARE PHARMA LIMITED
REGISTERED NUMBER: 08078767

BALANCE SHEET
AS AT 31 MARCH 2024

2024
2023
Note
£
£

  

Current assets
  

Cash at bank and in hand
 4 
100
100

  
100
100

Total assets less current liabilities
  
 
 
100
 
 
100

  

Net assets
  
100
100


Capital and reserves
  

Called up share capital 
  
100
100

  
100
100


For the year ended 31 March 2024 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Miss H Patel
Director

Date: 6 August 2024

The notes on pages 5 to 6 form part of these financial statements.

Page 3

 
PROCARE PHARMA LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2024


Called up share capital
Total equity

£
£

At 1 April 2023
100
100
Total comprehensive income for the year
-
-


At 31 March 2024
100
100



STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2023


Called up share capital
Total equity

£
£

At 1 April 2022
100
100
Total comprehensive income for the year
-
-


At 31 March 2023
100
100


The notes on pages 5 to 6 form part of these financial statements.

Page 4

 
PROCARE PHARMA LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1.


General information

Procare Pharma Limited (the “Company”) is a private company limited by shares and incorporated, domiciled and registered in England in the United Kingdom. The address of the registered office is given on the company information page. The nature of the company's operations and its principal activities are set out in the directors' report on page 1.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The functional currency of Procare Pharma Limited is considered to be pounds sterling because that is the currency of the primary economic environment in which the Company operates. The financial
statements are also presented in pounds sterling and rounded to nearest £.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

The following account policies have been applied:

  
2.2

Financial Reporting Standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":
the requirements of Section 7 Statement of Cash Flows;
the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
the requirements of Section 33 Related Party Disclosures paragraph 33.7.


 
2.3

Going concern

As the Directors do not intend to acquire a replacement trade, the Directors have not prepared the financial statements on a going concern basis.


3.


Judgments in applying accounting policies and key sources of estimation uncertainty

No significant judgements or key accounting estimates have been applied in the preparation of these financial statements.

Page 5

 
PROCARE PHARMA LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

4.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
100
100

100
100



5.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



100 (2023 - 100) Ordinary shares of £1.00 each
100
100



6.


Controlling party

The company's controlling party is Mrs N K Patel.

Page 6